These agreements are designed to be a flexible financing solution to support operations while finalizing a strategic partnership Company is in advanced stages to finalize a strategic transaction with ...

BioAtla (BCAB) has entered into definitive agreements with certain institutional investors for the issuance and sale of 9,679,158 shares of its common stock in a registered direct offering. Each share ...

BioAtla, Inc. has called a special meeting of stockholders for March 4, 2026, to be held virtually via live webcast, with all materials delivered both in paper form and online. Stockholders of record ...

BioAtla will receive an initial $5 million for general operating and Phase 3 clinical trial expenses to advance Oz-V in 2L+ OPSCC with the remaining $35 million anticipated to close in Q1 2026.

BioAtla ( (BCAB)) has issued an announcement. On February 6, 2026, BioAtla, Inc. disclosed that it had received a Nasdaq determination to suspend trading of its common stock, citing the company’s ...

SAN DIEGO, April 30, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ...

BioAtla, Inc. reported promising results for its treatment, Mecbotamab Vedotin (Mec-V), in patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS). At the ...

FDA alignment on Phase 3 ozuriftamab vedotin (Oz-V) trial design, including dosing regimen and endpoints to support potential accelerated approval Company continues preparations for enabling ...

SAN DIEGO, Dec. 31, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc., a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for ...